JP2025506001A - 225-アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 - Google Patents
225-アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 Download PDFInfo
- Publication number
- JP2025506001A JP2025506001A JP2024546261A JP2024546261A JP2025506001A JP 2025506001 A JP2025506001 A JP 2025506001A JP 2024546261 A JP2024546261 A JP 2024546261A JP 2024546261 A JP2024546261 A JP 2024546261A JP 2025506001 A JP2025506001 A JP 2025506001A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- acid
- mbq
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263308211P | 2022-02-09 | 2022-02-09 | |
| US63/308,211 | 2022-02-09 | ||
| PCT/IB2023/051159 WO2023152671A1 (en) | 2022-02-09 | 2023-02-09 | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506001A true JP2025506001A (ja) | 2025-03-05 |
| JP2025506001A5 JP2025506001A5 (cg-RX-API-DMAC7.html) | 2026-02-06 |
Family
ID=85328574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024546261A Pending JP2025506001A (ja) | 2022-02-09 | 2023-02-09 | 225-アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250161502A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4475900A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506001A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118647415A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023152671A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2025058000A1 (cg-RX-API-DMAC7.html) | 2023-09-13 | 2025-03-20 | ||
| WO2025218879A1 (en) * | 2024-04-15 | 2025-10-23 | Itm Technologies Munich Se | Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same |
| WO2025255396A1 (en) * | 2024-06-05 | 2025-12-11 | Ariceum Therapeutics Gmbh | Radiopharmaceutical composition and methods |
| WO2026089608A2 (en) | 2024-10-21 | 2026-04-30 | Erasmus University Medical Center Rotterdam | Radiopharmaceuticals |
| WO2026120497A1 (en) * | 2024-12-05 | 2026-06-11 | Novartis Ag | Stable radionuclide complex solutions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1606012A2 (en) * | 2003-03-25 | 2005-12-21 | Sloan-Kettering Institute For Cancer Research | Methods for protection from toxicity of alpha emitting elements during radioimmunotherapy |
| KR20250057132A (ko) | 2016-03-22 | 2025-04-28 | 더 존스 홉킨스 유니버시티 | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 |
| US11478558B2 (en) * | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| PL3997103T3 (pl) | 2019-07-08 | 2025-03-24 | 3B Pharmaceuticals Gmbh | Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie |
| CN118955620A (zh) | 2019-07-08 | 2024-11-15 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| CA3185968A1 (en) * | 2020-07-13 | 2022-01-20 | Tony Lahoutte | Antibody fragment against folr1 |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4274835A1 (en) | 2021-01-07 | 2023-11-15 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4122499A1 (en) | 2021-07-23 | 2023-01-25 | 3B Pharmaceuticals GmbH | Fibroblast activation protein inhibitors and use thereof |
-
2023
- 2023-02-09 EP EP23706856.4A patent/EP4475900A1/en active Pending
- 2023-02-09 WO PCT/IB2023/051159 patent/WO2023152671A1/en not_active Ceased
- 2023-02-09 CN CN202380018997.0A patent/CN118647415A/zh active Pending
- 2023-02-09 US US18/836,576 patent/US20250161502A1/en active Pending
- 2023-02-09 JP JP2024546261A patent/JP2025506001A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023152671A1 (en) | 2023-08-17 |
| CN118647415A (zh) | 2024-09-13 |
| US20250161502A1 (en) | 2025-05-22 |
| EP4475900A1 (en) | 2024-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Functionally versatile and highly stable chelator for 111In and 177Lu: Proof-of-principle prostate-specific membrane antigen targeting | |
| CN108290924B (zh) | 肽硫脲衍生物、含有其的放射性同位素标记化合物、和含有该化合物作为活性成分的用于治疗或诊断前列腺癌的药物组合物 | |
| AU2014396468B2 (en) | Modified cyclopentapeptides and uses thereof | |
| US20250161502A1 (en) | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent | |
| JP2020528461A (ja) | デュアルモードの放射性トレーサーおよび療法剤 | |
| JP7673056B2 (ja) | Grprアンタゴニストを放射標識するための方法及びそれらのキット | |
| JP7762648B2 (ja) | 安定した濃縮放射性医薬組成物 | |
| SA96160495B1 (ar) | استخدام ببتيدات سوماتوستاتين somatostatin peptides معقدة عديدة للتصوير الحيوي للأورام وانتشار الورم الموطب لمستقبل السوماتوستاتين somatostatin receptor | |
| KR20250073273A (ko) | 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도 | |
| JP7646637B2 (ja) | 画像化及び治療用組成物 | |
| Läppchen et al. | In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector | |
| US7122622B2 (en) | Peptide compounds having improved binding affinity to somatostatin receptors | |
| JP2023506297A (ja) | 癌のイメージングおよび治療のための修飾されたgrprアンタゴニストペプチド | |
| JP6410339B2 (ja) | 放射性核種標識オクトレオチド誘導体 | |
| EP4631959A2 (en) | Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy | |
| US20250313579A1 (en) | Ligand compounds comprising a chelating group as a bridging group | |
| US20240254085A1 (en) | Chelators for radiometals and methods of making and using same | |
| CN113195005A (zh) | 包含放射性标记的grpr拮抗剂和表面活性剂的药物组合物 | |
| RU2839656C1 (ru) | Стабильная концентрированная радиофармацевтическая композиция | |
| US12486294B2 (en) | Radioisotope labeled compound for imaging or treatment of prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260129 |